MYCN Amplifications

Showing: 1 - 1 of 1 Articles

ProLynx announces initiation of Phase I/II clinical trial of its DNA-damaging agent PLX038 in patients with rare CNS tumors at the National Cancer Institute (NCI)

ProLynx Inc. announced today that the first patient was treated with PLX038 (PEGylated SN-38) in …